AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14614165 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg CTLA4Ig per kilogram
Number of subjects: 339
Study 14614165 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg CTLA4Ig per kilogram
Number of subjects: 339
Study 14614165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study 11374857 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release niacin
Number of subjects: 0
Study 11374857 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (Niaspan)
Number of subjects: 0
Study 8780292 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional video review of VT1 prior to VT2
Number of subjects: 29
Study 8780292 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instructional review)
Number of subjects: 29
Study 1385567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg intravenous doses, two doses: one before anesthesia induction and one 8 hours later)
Number of subjects: 50
Study 1385567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two doses of placebo vehicle: one before anesthesia induction and one 8 hours later)
Number of subjects: 50
Study 6881960 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.8 mg
Number of subjects: 12
Study 6881960 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 1.6 mg
Number of subjects: 12
Study 6881960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31591063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus erlotinib (150 mg/day erlotinib, 10 mg/kg ramucirumab every 2 weeks)
Number of subjects: 449
Study 31591063 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus erlotinib (150 mg/day erlotinib)
Number of subjects: 449
Study 31591063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus erlotinib
Number of subjects: 449
Study 31591063 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus erlotinib
Number of subjects: 449
Study 29118087 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (BMI 25.0-29.9 kg/m2)
Number of subjects: 441
Study 29118087 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese (BMI ≥30 kg/m2)
Number of subjects: 441
Study 29118087 — intervention group
Group type: COMPARATOR
Intervention: Normal weight (BMI 18.5-24.9 kg/m2; reference group)
Number of subjects: 441
Study 27356991 — intervention group
Group type: EXPERIMENTAL
Intervention: My Own Health Report (MOHR)
Number of subjects: 18
Study 27356991 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 18
Study 25204098 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-year alcohol prevention program (Program Domowych Detektywów and Fantastyczne Mozliwości)
Number of subjects: 802
Study 25204098 — intervention group
Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 802
Study 21451504 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐4878691 (3, 6, and 9 mg doses, twice a week for 2 weeks)
Number of subjects: 0
Study 21451504 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐4878691 (9 mg dose)
Number of subjects: 0
Study 21451504 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐4878691
Number of subjects: 0
Study 19653753 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct grip with correct goal location
Number of subjects: 0
Study 19653753 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-related objects (e.g., cup) with movement toward the subject's body
Number of subjects: 0
Study 19653753 — intervention group
Group type: EXPERIMENTAL
Intervention: World-related objects (e.g., pincers) with movement in the opposite direction
Number of subjects: 0
Study 19653753 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual semantics retrieval (Experiment 4)
Number of subjects: 0
Study 16965983 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (enoxaparin, 4000 IU/d, n = 56 hypertensive patients)
Number of subjects: 94
Study 16965983 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 38 hypertensive women)
Number of subjects: 94
Study 16965983 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 30)
Number of subjects: 94
Study 14976884 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Zhizhu pill (ZZP) 100 ml, twice daily, orally taken half an hour before meal
Number of subjects: 63
Study 14976884 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 0.15 g, twice daily and Cisapride 10 mg, three times a day, orally taken before meal
Number of subjects: 63
Study 11122219 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 26
Study 11122219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9382344 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical advice (Group 1)
Number of subjects: 353
Study 9382344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (Group 2)
Number of subjects: 353
Study 9382344 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group 3)
Number of subjects: 353
Study 8407393 — intervention group
Group type: EXPERIMENTAL
Intervention: IUdR 96 hr infusion schedule
Number of subjects: 79
Study 8407393 — intervention group
Group type: EXPERIMENTAL
Intervention: IUdR 48 hr infusion schedule
Number of subjects: 79
Study 8407393 — intervention group
Group type: EXPERIMENTAL
Intervention: IUdR 24 hr infusion schedule
Number of subjects: 79
Study 8407393 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 79
Study 2426940 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% permethrin cream rinse
Number of subjects: 573
Study 2426940 — intervention group
Group type: COMPARATOR
Intervention: 1% lindane shampoo
Number of subjects: 573
Study 4582638 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental infection with Mycoplasma pneumoniae
Number of subjects: 67
Study 30658657 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth cancer pain assessment intervention delivered via the QStream online platform over four weeks.
Number of subjects: 0
Study 30658657 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group (not receiving the mHealth intervention).
Number of subjects: 0
Study 27682748 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with epinephrine
Number of subjects: 90
Study 27682748 — intervention group
Group type: COMPARATOR
Intervention: Normal saline with epinephrine
Number of subjects: 90
Study 27682748 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative phenazopyridine
Number of subjects: 90
Study 27682748 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 90
Study 26063688 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP with best supportive care (BSC)
Number of subjects: 278
Study 26063688 — intervention group
Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 278
Study 26063688 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 278
Study 26063688 — intervention group
Group type: COMPARATOR
Intervention: BSC
Number of subjects: 278
Study 24622369 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 899
Study 24622369 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 899
Study 24622369 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 899
Study 24622369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 899
Study 22092641 — intervention group
Group type: EXPERIMENTAL
Intervention: Moraxella bovis autogenous vaccine
Number of subjects: 369
Study 22092641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study 19747937 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-Wise intervention (n=72)
Number of subjects: 143
Study 19747937 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group (n=71)
Number of subjects: 143
Study 16701090 — intervention group
Group type: EXPERIMENTAL
Intervention: Age greater than 70 years
Number of subjects: 300
Study 16701090 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended resection
Number of subjects: 300
Study 16701090 — intervention group
Group type: EXPERIMENTAL
Intervention: Main pancreatic duct diameter of 3 mm or less
Number of subjects: 300
Study 14978607 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and scheduled-toileting intervention (provided every two hours, four times per day, five days a week for 32 weeks)
Number of subjects: 89
Study 14978607 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 89
Study 14978607 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and scheduled-toileting intervention
Number of subjects: 89
Study 11408369 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice daily)
Number of subjects: 12
Study 9200633 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the Ottawa ankle rules during the intervention period.
Number of subjects: 4210
Study 9200633 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention during the intervention period).
Number of subjects: 4210
Study 9200633 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintervention period with posters alone to sustain the effect.
Number of subjects: 4210
Study 8290859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg daily for 28 days)
Number of subjects: 0
Study 8290859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2975285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 200 micrograms
Number of subjects: 10
Study 2975285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 80 micrograms
Number of subjects: 10
Study 2975285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (both dosages)
Number of subjects: 10
Study 2975285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 10
Study 2975285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30571402 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined serum iron
Number of subjects: 48972
Study 30571402 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined ferritin
Number of subjects: 48972
Study 30571402 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined transferrin saturation
Number of subjects: 48972
Study 30571402 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined transferrin
Number of subjects: 48972
Study 26492971 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary program (geriatric consultation, in-hospital rehabilitation, discharge planning, rehabilitation at home for 3 months)
Number of subjects: 153
Study 26492971 — intervention group
Group type: COMPARATOR
Intervention: Usual care (in-hospital rehabilitation and occasional discharge planning)
Number of subjects: 153
Study 24230461 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology exercises
Number of subjects: 61
Study 24230461 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude exercises
Number of subjects: 61
Study 24230461 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal strengths exercises
Number of subjects: 61
Study 24230461 — intervention group
Group type: EXPERIMENTAL
Intervention: Other positive psychology exercises
Number of subjects: 61
Study 24230461 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study 22107114 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal deaths due to prematurity/low birth-weight
Number of subjects: 238
Study 22107114 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal deaths due to intrapartum-related causes (birth asphyxia)
Number of subjects: 238
Study 22107114 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal deaths due to infections
Number of subjects: 238
Study 22107114 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal deaths due to congenital malformation
Number of subjects: 238
Study 22107114 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal deaths occurring within the first 24 hours after delivery
Number of subjects: 238
Study 20444662 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 0
Study 20444662 — intervention group
Group type: COMPARATOR
Intervention: glimepiride+metformin
Number of subjects: 0
Study 20444662 — intervention group
Group type: COMPARATOR
Intervention: metformin
Number of subjects: 0
Study 18721198 — intervention group
Group type: EXPERIMENTAL
Intervention: Single gram of intramuscular ceftriaxone
Number of subjects: 400
Study 18721198 — intervention group
Group type: COMPARATOR
Intervention: 3-day course of oral ciprofloxacin
Number of subjects: 400
Study 18721198 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral 500 mg of ciprofloxacin
Number of subjects: 400
Study 18721198 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 400
Study 17013573 — intervention group
Group type: EXPERIMENTAL
Intervention: TAX/RT (paclitaxel 90 mg/m² or docetaxel 35 mg/m²)
Number of subjects: 36
Study 17013573 — intervention group
Group type: COMPARATOR
Intervention: TAX/CIS/RT (paclitaxel 135 mg/m² d1 and cisplatin 20 mg/m² d1-5 q28)
Number of subjects: 36
Study 17013573 — intervention group
Group type: EXPERIMENTAL
Intervention: TAX/RT
Number of subjects: 36
Study 17013573 — intervention group
Group type: COMPARATOR
Intervention: TAX/CIS/RT
Number of subjects: 36
Study 15226460 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP Step 2 high‐fish diet (n = 11, 26% of energy as fat, 4.5% as saturated fat, and 15 mg cholesterol/MJ)
Number of subjects: 22
Study 15226460 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP Step 2 low‐fish diet (n = 11, 26% of energy as fat, 4.0% as saturated fat, and 11 mg cholesterol/MJ)
Number of subjects: 22
Study 15226460 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 22
Study 15226460 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP Step 2 high‐fish diet
Number of subjects: 22
Study 15226460 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP Step 2 low‐fish diet
Number of subjects: 22
Study 15226460 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither diet
Number of subjects: 22
Study 10949017 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dilator (A)
Number of subjects: 15
Study 10949017 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (P)
Number of subjects: 15
Study 10949017 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 15
Study 14685384 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat oral supplement (Group I)
Number of subjects: 14
Study 14685384 — intervention group
Group type: COMPARATOR
Intervention: Standard diet without supplement (Control Group II)
Number of subjects: 14
Study 8457050 — intervention group
Group type: COMPARATOR
Intervention: 30 ml 2% lidocaine, followed by 10 ml every 45 min (Control)
Number of subjects: 100
Study 8457050 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ml of 3% chloroprocaine (containing EDTA), plus 5 ml every 45 min
Number of subjects: 100
Study 8457050 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml of 3% chloroprocaine plus 10 ml every 45 min
Number of subjects: 100
Study 8457050 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml of 3% chloroprocaine (containing metabisulfite as the preservative but no EDTA) plus 10 ml every 45 min
Number of subjects: 100
Study 8457050 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml of 3% chloroprocaine with the pH adjusted to 7.3, plus 10 ml every 45 min
Number of subjects: 100
Study 3836297 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (100, 200, 400, 600 mg BID)
Number of subjects: 35
Study 3836297 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 or 50 mg BID)
Number of subjects: 35
Study 31685227 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum ferritin values
Number of subjects: 0
Study 31685227 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ferritin of 17 μg/L
Number of subjects: 0
Study 30224032 — intervention group
Group type: EXPERIMENTAL
Intervention: Rise of 1st follow-up sodium (Na) at day 3 (n=43)
Number of subjects: 89
Study 30224032 — intervention group
Group type: COMPARATOR
Intervention: No rise in 1st follow-up sodium (Na) at day 3 (n=46)
Number of subjects: 89
Study 30224032 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression analysis for rise in 1st follow-up Na
Number of subjects: 89
Study 26974582 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring during Phase 1 (6-month intervention)
Number of subjects: 167
Study 26974582 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring during Phase 2 (12-month extended care)
Number of subjects: 167
Study 26974582 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring during Phase 2
Number of subjects: 167
Study 25240564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone-augmented percutaneous discectomy (OPLD)
Number of subjects: 147
Study 25240564 — intervention group
Group type: COMPARATOR
Intervention: Caudal epidural
Number of subjects: 147
Study 22781573 — intervention group
Group type: EXPERIMENTAL
Intervention: Infective group (patients with fungal infections)
Number of subjects: 697
Study 20074265 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal abdominal hysterectomy (SH)
Number of subjects: 200
Study 20074265 — intervention group
Group type: EXPERIMENTAL
Intervention: Total abdominal hysterectomy (TH)
Number of subjects: 200
Study 17299465 — intervention group
Group type: EXPERIMENTAL
Intervention: High MUFA diet
Number of subjects: 18
Study 17299465 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control diet
Number of subjects: 18
Study 16153351 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive care
Number of subjects: 466
Study 16153351 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic care
Number of subjects: 466
Study 12847531 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day antibiotic therapy (AT)
Number of subjects: 26
Study 12847531 — intervention group
Group type: COMPARATOR
Intervention: 4-day antibiotic therapy (AT)
Number of subjects: 26
Study 12847531 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil values (NV), C-reactive protein (CRP), procalcitonin (PCT)
Number of subjects: 26
Study 10584976 — intervention group
Group type: COMPARATOR
Intervention: Vomitron 8
Number of subjects: 0
Study 10584976 — intervention group
Group type: COMPARATOR
Intervention: Vomitron 4
Number of subjects: 0
Study 10584976 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofran (reference)
Number of subjects: 0
Study 10584976 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Zofran
Number of subjects: 0
Study 8884403 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech therapy with mothers present
Number of subjects: 0
Study 8884403 — intervention group
Group type: COMPARATOR
Intervention: Speech therapy without mothers present
Number of subjects: 0
Study 1869010 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit drain (non-suction)
Number of subjects: 0
Study 1869010 — intervention group
Group type: COMPARATOR
Intervention: Redon drain (established type)
Number of subjects: 0
Study 6134181 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar instillation of Dermatophagoides pteronyssinus allergen
Number of subjects: 7
Study 6134181 — intervention group
Group type: COMPARATOR
Intervention: Control lung (no allergen instillation)
Number of subjects: 7
Study 6134181 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 controls)
Number of subjects: 7
Study 31007170 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel (5 mL applied topically to the cervix 5 minutes prior to paracervical blockade)
Number of subjects: 88
Study 31007170 — intervention group
Group type: COMPARATOR
Intervention: Paracervical blockade alone (placebo)
Number of subjects: 88
Study 29318656 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (an androgen bioactivation inhibitor)
Number of subjects: 2181
Study 29318656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2181
Study 26961599 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals supplemented with 1.4 g of cocoa extract (645 mg polyphenols)
Number of subjects: 50
Study 26961599 — intervention group
Group type: COMPARATOR
Intervention: Meals without cocoa supplementation (Control)
Number of subjects: 50
Study 24743880 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-febrile malaria treatment
Number of subjects: 0
Study 23123020 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A H1N1/2009 vaccine
Number of subjects: 58
Study 20663659 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE plus HIFU
Number of subjects: 89
Study 20663659 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 89
Study 17210728 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% chlorhexidine skin-cleansing
Number of subjects: 17530
Study 17210728 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 17530
Study 16033621 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 758
Study 16033621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 758
Study 11978262 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat cereal group (5.52 g/day beta-glucan)
Number of subjects: 18
Study 11978262 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber cereal control group (less than 1.0 g/day total fiber)
Number of subjects: 18
Study 9417143 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP vaccine
Number of subjects: 10271
Study 9417143 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccine
Number of subjects: 10271
Study 9417143 — intervention group
Group type: COMPARATOR
Intervention: DT vaccine
Number of subjects: 10271
Study 8534671 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg daily simvastatin
Number of subjects: 621
Study 8534671 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg daily simvastatin
Number of subjects: 621
Study 8534671 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 621